scholarly journals Primary B-cell MALT lymphoma of the palate: A case report and distinction from benign lymphoid hyperplasia (pseudolymphoma)

2012 ◽  
Vol 16 (1) ◽  
pp. 97 ◽  
Author(s):  
RV Subramanyam ◽  
Grewal Harshaminder ◽  
Shankari Madhu ◽  
Ravi Narula ◽  
JawandaKaur Manveen
Keyword(s):  
Case Report ◽  
B Cell ◽  
Malt Lymphoma ◽  
Lymphoid Hyperplasia ◽  
Benign Lymphoid Hyperplasia

Benign Lymphoid Hyperplasia of the Tongue Masquerading as Carcinoma: Case Report and Literature Review

2005 ◽  
Vol 6 (3) ◽  
pp. 111-119 ◽  
Author(s):  
Sunitha Carnelio ◽  
Gabriel Rodrigues
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Lymphoid Hyperplasia ◽  
Germinal Centers ◽  
Major Surgery ◽  
Benign Lymphoid Hyperplasia ◽  
Mononuclear Infiltrate ◽  
Carcinoma Of The Tongue

Abstract Lymphoid hyperplasia of the tongue is a very rare benign lymphoproliferative lesion that closely resembles carcinoma or lymphoma, clinically or histopathologically. A case of benign lymphoid hyperplasia (BLH) of the tongue is reported. Clinically this lesion presented as a painless ulcer, which mimicked carcinoma of the tongue. Microscopy showed typical histologic features of multiple germinal centers with a rim of small mature lymphocytes together with a mixed, mainly mononuclear infiltrate which clinched the diagnosis of benign lymphoid hyperplasia. This diagnosis averted extensive investigations and major surgery. The etiology of these lesions is unknown. Their distinction from carcinoma and lymphoma is discussed. Citation Carnelio S, Rodrigues G. Benign Lymphoid Hyperplasia of the Tongue Masquerading as Carcinoma: Case Report and Literature Review. J Contemp Dent Pract 2005 August;(6)3:111-119.

Colonic Marginal Zone B-Cell Lymphoma (MALT Lymphoma) in a Patient Negative for H. pylori: Case Report

2018 ◽  
Vol 113 (Supplement) ◽  
pp. S937-S938
Author(s):  
Gurjiwan S. Virk ◽  
Jennifer Copare ◽  
Sven Hida ◽  
Seth J. Richter
Keyword(s):  
Case Report ◽  
B Cell ◽  
Malt Lymphoma ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
H Pylori

Rectal lymphoid hyperplasia resembling polypoid-type malt-lymphoma: A case report

2008 ◽  
Vol 40 (10) ◽  
pp. A101
Author(s):  
G. Lombardi ◽  
M.T. Illiceto ◽  
G. Lisi ◽  
M. Filippone ◽  
C. Rossi ◽  
...  
Keyword(s):  
Case Report ◽  
Malt Lymphoma ◽  
Lymphoid Hyperplasia

scholarly journals Primary breast mucosa-associated lymphoid tissue (MALT) lymphoma transformation to diffuse large B-cell lymphoma: A case report

2011 ◽  
Author(s):  
Serife Hulya Arslan ◽  
Ummugul Uyeturk ◽  
Emre Tekgunduz ◽  
Sultan Cigdem Irkkan ◽  
Meltem Kurt Yuksel ◽  
...  
Keyword(s):  
Case Report ◽  
B Cell ◽  
Malt Lymphoma ◽  
Lymphoid Tissue ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Asynchronous Low-Grade Malignant B-cell MALT Lymphoma of Parotid Glands; A Case Report.

1995 ◽  
Vol 88 (11) ◽  
pp. 1439-1445 ◽  
Author(s):  
Hiroshi IWAI ◽  
Akiharu OKAMURA ◽  
Noriko SAKAIDA ◽  
Shugo SHIRAISHI ◽  
Masahiro YANAGIDA ◽  
...  
Keyword(s):  
Case Report ◽  
B Cell ◽  
Malt Lymphoma ◽  
Low Grade ◽  
Parotid Glands

scholarly journals Primary Breast Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Transformation to Diffuse Large B-cell Lymphoma: A Case Report

2012 ◽  
Vol 29 (3) ◽  
pp. 274-277 ◽  
Author(s):  
Serife Hulya Arslan ◽  
Ummugul Uyeturk ◽  
Emre Tekgunduz ◽  
Sultan Cigdem Irkkan ◽  
Meltem Yuksel Kurt ◽  
...  
Keyword(s):  
Case Report ◽  
B Cell ◽  
Malt Lymphoma ◽  
Lymphoid Tissue ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Transformation of MALT lymphoma of rectosigmoid colon to diffuse large B-cell lymphoma: a case report

2021 ◽  
Vol 98 (1) ◽  
pp. 118-120
Author(s):  
Masao Kusano ◽  
Masaki Tosa ◽  
Tomoyuki Ikeda ◽  
Seiichi Takahashi ◽  
Shinichi Ikeya
Keyword(s):  
Case Report ◽  
B Cell ◽  
Malt Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Rectosigmoid Colon ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Extranodal noncutaneous lymphoid hyperplasias represent a continuous spectrum of B-cell neoplasia: demonstration by molecular genetic analysis

Blood ◽  
1989 ◽  
Vol 73 (6) ◽  
pp. 1635-1645 ◽  
Author(s):  
DM Knowles ◽  
E Athan ◽  
A Ubriaco ◽  
L McNally ◽  
G Inghirami ◽  
...  
Keyword(s):  
B Cell ◽  
Malignant Lymphoma ◽  
Dna Sequences ◽  
Lymphoid Hyperplasia ◽  
Chain Gene ◽  
Gene Rearrangements ◽  
Immunoglobulin Gene ◽  
Lymphoid Neoplasms ◽  
Benign Lymphoid Hyperplasia ◽  
Ebv Dna

We investigated 16 lymphoid proliferations occurring in the ocular adnexa, salivary glands, breast, and thyroid gland and satisfying the histopathologic and immunophenotypic criteria of benign lymphoid hyperplasia for the presence of clonal rearrangements of the antigen receptor, c-myc, bcl-1, and bcl-2 genes and Epstein-Barr virus (EBV) DNA sequences. Each of these 16 extranodal, noncutaneous lymphoid neoplasms exhibited clonal immunoglobulin heavy and/or light chain and lacked T-cell receptor (TCR) beta-chain gene rearrangements. The patterns of immunoglobulin gene rearrangements included solitary and multiple barely perceptible to faint bands, solitary clear and definite bands, and solitary high-intensity bands superimposed on a background of multiple less-intense bands. Three ocular adnexal lymphoid neoplasms exhibited bcl-1 or bcl-2 gene rearrangements. None of the 16 lymphoid neoplasms contained EBV DNA sequences. Two patients developed a histopathologically confirmed malignant lymphoma in an extranodal site. None of the remaining 14 patients developed additional lymphoid neoplasms during a mean follow-up period of 30 months, despite conservative therapy. These results demonstrate that extranodal, noncutaneous lymphoid neoplasms meeting the histopathologic and immunophenotypic criteria for benign lymphoid hyperplasia frequently contain occult monoclonal and oligoclonal B-cell populations representing a continuous and progressive spectrum of B-cell neoplasia up to and including malignant lymphoma.

Rituximab and yttrium-90 ibritumomab tiuxetan radioimmunotherapy as treatment options in patients with indolent lymphoma of the orbit

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 15532-15532
Author(s):  
B. Esmaeli ◽  
B. Pro ◽  
M. Saville ◽  
P. Mc Laughlin
Keyword(s):  
Monoclonal Antibodies ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Lymphoid Hyperplasia ◽  
Ibritumomab Tiuxetan ◽  
Benign Lymphoid Hyperplasia ◽  
Orbital Lymphoma ◽  
Clinical Records ◽  
Yttrium 90

15532 Objective: To report a cohort of patients with lymphoid tumors of the orbit whose disease responded to immunotherapy with rituximab alone or rituximab followed by Zevalin (yttrium-90 ibritumomab tiuxetan). Methods: Between October 2002 and June 2005, 9 patients with indolent non-Hodgkin’s lymphoma and 1 with orbital benign lymphoid hyperplasia were treated with monoclonal antibodies against CD20. 6 patients with orbital lymphoma (3 follicular B-cell, 2 MALT, and 1 mantle cell lymphoma) received rituximab followed by Zevalin. 2 patients with indolent orbital lymphoma (one with follicular B cell and the other with small lymphocytic lymphoma) and 1 patient with benign lymphoid hyperplasia received rituximab alone. 3 out of the 6 patients who received Zevalin were part of a prospective trial evaluating the efficacy of Zevalin for indolent B-cell lymphoma of the orbit; the rest were treated in other trials at M. D. Anderson. Clinical records and imaging studies were reviewed to document response. Results: 4 men and 5 women were between23 and 83 years old (median age, 63 years). Of the 8 patients with orbital lymphoma, 4 had stage IE, 4 had stage IV, and 6 had previously untreated disease. All 9 patients experienced resolution of the orbital tumor in response to monoclonal antibodies against CD20. Follow-up time ranged from 6 to 32 months (mean, 12 months) after completion of immunotherapy. There were no serious systemic or ocular side effects during the study period. The most common side effect was mild fatigue. All 6 patients treated with Zevalin had transient pancytopenia which normalized within 3 months. Conclusions: Rituximab and Zevalin may be considered as alternative treatment modalities to radiotherapy for indolent B-cell lymphoma or MALT of the orbit. Systemic targeted immunotherapy may potentially have the advantage of lower rate of distant (out-of-field) relapse and less ocular toxicity compared with radiotherapy; these potential advantages would have to be verified in long-term studies and in larger number of patients. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document